Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1)

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.16
Views: 1342

Dr Arndt Stahler - University of Munich, Munich, Germany

Dr Stahler speaks with ecancer at ESMO 2016 about his research targeting FGF2 expression against chemoresistance in colorectal cancer (CRC) 3 cell lines, with expression levels have a potentially predictive value for patient response.

He summarises the results in cell lines and how this has translated to predicted and actual patient response.

Dr Stahler notes that this was an exploratory trial, and considers avenues of further upcoming validation trials.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation